Clinical consequences of disseminating the rosiglitazone FDA safety warning.

The American journal of managed care

Volumn 16, Issue 5, 2010, Pages

  Orrico, Kathleen B ^a   Lin, Joyce K ^b   Wei, Amy ^b   Yue, Henry ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; ROSIGLITAZONE;

ARTICLE; CLINICAL PRACTICE; DECISION MAKING; DRUG UTILIZATION; FOOD AND DRUG ADMINISTRATION; GLYCEMIC INDEX; HUMAN; MEDICAL AUDIT; POSTMARKETING SURVEILLANCE; PRIMARY HEALTH CARE; RETROSPECTIVE STUDY; UNITED STATES;

CALIFORNIA; DECISION MAKING; DRUG UTILIZATION; GLYCEMIC INDEX; HUMANS; HYPOGLYCEMIC AGENTS; MEDICAL AUDIT; PHYSICIAN'S PRACTICE PATTERNS; PRIMARY HEALTH CARE; PRODUCT SURVEILLANCE, POSTMARKETING; RETROSPECTIVE STUDIES; THIAZOLIDINEDIONES; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 77955907527     PISSN: None     EISSN: 19362692     Source Type: Journal    
DOI: None     Document Type: Article

References (0)